{"id":55631,"date":"2022-12-22T09:52:41","date_gmt":"2022-12-22T09:52:41","guid":{"rendered":"https:\/\/touchoncology.com\/?post_type=media_gallery&p=55631"},"modified":"2022-12-22T09:52:41","modified_gmt":"2022-12-22T09:52:41","slug":"saskia-middeldorp-ash-2022-the-efficacy-of-low-molecular-weight-heparin-in-women-with-recurrent-miscarriage-and-inherited-thrombophilia-the-alife-2-trial","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/haematology\/conference-hub\/saskia-middeldorp-ash-2022-the-efficacy-of-low-molecular-weight-heparin-in-women-with-recurrent-miscarriage-and-inherited-thrombophilia-the-alife-2-trial\/","title":{"rendered":"Saskia Middeldorp, ASH 2022: The efficacy of low-molecular-weight heparin in women with recurrent miscarriage and inherited thrombophilia – the ALIFE 2 trial"},"content":{"rendered":"
Studies have linked recurrent miscarriage with inherited thrombophilia. The ALIFE 2 trial aimed to assess the efficacy of low-molecular-weight heparin (LMWH) therapy in women with recurrent miscarriage and inherited thrombophilia. In this touchONCOLOGY interview, we speak with<\/span> Professor Saskia Middeldorp <\/b>(Radboud University Medical Center, Nijmegen, Netherlands) to discuss the ALIFE 2 clinical trial and the impact the findings have for women with inherited thrombophilia.\u00a0<\/span><\/p>\n The abstract entitled \u2018<\/span>Low-Molecular-Weight Heparin Versus Standard Pregnancy Care for Women with Recurrent Miscarriage and Inherited Thrombophilia (ALIFE2): An Open-Label, Phase III Randomized Controlled Trial<\/span><\/a>\u2019 (Abstract #LB-5) was presented at <\/span>ASH Annual Meeting<\/span><\/a>, 10\u201313, December, 2022.<\/span><\/p>\n Questions<\/b>:<\/span><\/p>\n Disclosures<\/b>: Saskia Middeldorp is on the advisory board and has received honoraria from Aspen, Pfizer and Viatris. She has received grant\/research support from Aspen and Pfizer.<\/span><\/p>\n Support<\/b>: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.<\/span><\/p>\n Filmed as a highlight of <\/i><\/b>ASH 2022<\/i><\/b><\/a><\/p>\n\n